Winning for the third time in a row! Medicilon won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year"

 On April 30, the highly anticipated "The 4th Pharmaceutical Innovation Award" event came to a successful conclusion.  At this event gathering industry elites, Medicilon USA Corp. (Medicilon) stood out with its cutting-edge innovative technology and excellent service capabilities, and won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year".

Winning this honor for the third time undoubtedly represents a high recognition and affirmation of Medicilon's twenty years of empowerment in drug innovation!

The "Pharmaceutical Innovation Award" is organized by the Securities Times in 2020, aiming to promote the improvement of drug innovation capabilities by selecting outstanding drug innovation projects, outstanding companies and outstanding figures in China.  The selection expert committee conducts selection based on the "Finance - Innovative Drug Index" database, drug evaluation and other related factors.  The event attracted more than 100 pharmaceutical companies, innovative drug R&D companies, and medical service companies to participate.  It has garnered widespread attention from industry experts and the academic community.

Deeply rooted in the genes of innovation, accumulating the driving force for development. Since its establishment twenty years ago, Medicilon has consistently adhered to driving comprehensive innovation through technological innovation, continuously investing in research and development resources, strengthening technological platform construction, and has grown into a leading one-stop preclinical research and development service platform in China. In 2023, Medicilon has been even more determined, adding several core technological platforms, such as the oligonucleotide drug development pilot platform, gene toxicity impurity assessment platform, and organoid platform based on iPS sources, further improving the one-stop innovative drug preclinical research and development service platform based on AI technology. At the same time, Medicilon has also strengthened the construction of the preclinical safety evaluation platform for traditional Chinese medicine, establishing platforms such as liver live puncture, muscle biopsy, and intrathecal injection platforms, providing solid support for early screening, druggability, and IND filing.

After twenty years of continuous hard work, Medicilon’s innovation tree has yielded fruitful results and is full of “fruits of empowerment”.  Since 2015, Medicilon has been involved in the research and development of 421 new drugs and generic drug projects, which have been approved by the CFDA/NMPA, the US FDA, and the Australian TGA to enter clinical trials, accelerating the R&D process of new drug development for clients. As of the end of 2023, Medicilon has served 50+ ADC clients, among which 24 have been approved by the NMPA and FDA and entered the clinical trial stage. It has also served 40+ oligonucleotide clients and 3+ PROTAC-related clients, and has assisted in the approval of clinical trials for 8 GLP-1 related drugs.

In the future, Medicilon will always stand at the forefront of innovation and new drug development in the biopharmaceutical industry, actively building a more complete, efficient, and high-quality innovative technology service platform to contribute to the global development of drug innovation!